Patent
Anti-angiogenic compositions and methods of use
Reads0
Chats0
TLDR
In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Abstract:
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.read more
Citations
More filters
Patent
Coated implantable medical device
TL;DR: A coated implantable medical device as discussed by the authors includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
Patent
Therapeutic inhibitor of vascular smooth muscle cells
TL;DR: In this paper, the authors present methods for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
Patent
Medical devices and applications of polyhydroxyalkanoate polymers
TL;DR: In this paper, the degradation times of polyhydroxyalkanoates are controlled under physiological conditions, and the degradation rates are controlled with less than one year under certain physiological conditions.
Patent
Silver implantable medical device
Anthony O. Ragheb,Brian L. Bates,Neal E. Fearnot,Thomas A. Osborne,Thomas G. Kozma,Joseph W. Roberts,William D. Voorhees +6 more
TL;DR: In this paper, a coronary stent implantable medical device is defined as a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
Patent
Drug coating with topcoat
Ni Ding,Michael N. Helmus +1 more
TL;DR: In this paper, a method for a coating an implantable device or prosthesis is described, which includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein.
References
More filters
Journal Article
Clinical toxicities encountered with paclitaxel (Taxol)
TL;DR: Although paclitaxel (TAXOL) appears to be one of the most promising antineoplastic agents of the last decade, with demonstrated activity in advanced and refractory ovarian, breast, lung, and head and neck cancers, most clinical oncologists have had little experience with the agent.
Journal ArticleDOI
Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator.
TL;DR: These studies emphasize in importance of control of activation in regulation collagenase activity, it is likely that rheumatoid synovium produces both latent collagenase and plasminogen activator; plAsmin is activated from its zymogen, plasmineogen, present in inflamed tissues, and in turn activates collagenase.
Journal ArticleDOI
Aliphatic polyesters. I. The degradation of poly(ϵ‐caprolactone) in vivo
TL;DR: The degradation of poly(ϵ-caprolactone) in rabbits, rats, and water was studied by measurement of changes in intrinsic viscosity, molecular weight, crystallinity, Young's modulus, and weight.
Journal Article
A Highly Conserved Vascular Permeability Factor Secreted by a Variety of Human and Rodent Tumor Cell Lines
TL;DR: The data suggest that a broad spectrum of tumor cells from several species, including humans, secretes a highly conserved molecule that enhances local vascular permeability and that this function may be important for tumor growth.
Patent
Intralumenal drug eluting prosthesis
Rodney G. Wolff,Vincent W. Hull +1 more
TL;DR: A prosthesis for insertion into a lumen to limit restenosis of the lumen is described in this article, where the prosthesis carries Restenosis-limiting drugs which elute after the device is positioned in the lume.